<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304511</url>
  </required_header>
  <id_info>
    <org_study_id>P08198</org_study_id>
    <nct_id>NCT01304511</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)速</brief_title>
  <official_title>Post-Marketing Surveillance Orgalutran (Ganirelix)速</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing surveillance is to identify problems and questions
      regarding the safety and efficacy of Orgalutran (Ganirelix)速 when used for the prevention of
      premature luteinizing hormone (LH) surges in women undergoing controlled ovarian
      hyperstimulation (COH) for assisted reproduction techniques (ART).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of retrieved oocytes by COH based on Per stage approach</measure>
    <time_frame>Baseline to End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>Baseline to End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Unlabeled (Unexpected) Adverse Drug Reactions</measure>
    <time_frame>Baseline to End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Labeled Adverse Drug Reactions</measure>
    <time_frame>Baseline to End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Non-serious Adverse Events</measure>
    <time_frame>Baseline to End of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse events by drug misuse/abuse or drug-drug interaction</measure>
    <time_frame>Baseline to End of Study</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">711</enrollment>
  <condition>Fertilization in Vitro</condition>
  <arm_group>
    <arm_group_label>Participants Treated</arm_group_label>
    <description>Women undergoing controlled ovarian COH for ART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orgalutran</intervention_name>
    <arm_group_label>Participants Treated</arm_group_label>
    <other_name>Ganirelix速</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women undergoing COH for ART
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be undergoing COH for ART

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Hypersensitivity to gonadotropin-releasing hormone (GnRH) or any other GnRH analogue

          -  Moderate or severe impairment of renal or hepatic function

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

